MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.32M
Average 0.99M
MLTX Net Income
Bottom-line profit after all expenses, interest, and taxes.
MoonLake ImmunotherapeuticsNASDAQ: MLTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$69.71M, compared with -$39.94M a year earlier. Trailing-twelve-month net income was -$257.08M.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$246.47M (-8.4%) for the fiscal year ending Dec 2026, a step up from the -91.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$69.71M-11.7% QoQ
- Last fiscal yearDec 2025
- -$227.32M-91.1% YoY
- LTMMar 2026
- -$257.08M-77.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -74.5% | -20.2% | +54.3 pp |
| 1 year | -91.1% | -8.4% | +82.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (227.32M) USD
- Year-over-year change
- -91.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (227.32M) | -91.1% |
| FY2024 | 2024-12-31 | (118.94M) | -230.3% |
| FY2023 | 2023-12-31 | (36.01M) | +27.9% |
| FY2022 | 2022-12-31 | (49.97M) | +6.8% |
| FY2021 | 2021-12-31 | (53.64M) | — |
Net Income vs competitors
How MLTX compares with its peers on the latest reported figures
- MLTX's LTM Mar 2026 net income of -$257.08M is the 10th highest of the 11 companies compared; the peer median is -$58.05M.
- Its year-over-year change of -77.0% is the 9th highest of 11, against a peer median of -33.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $294.88M | +220.5% | — | 42.0% | |
| LTM Mar 2026 | -$19.06M | -36.2% | — | — | |
| LTM Mar 2026 | -$26.79M | +81.0% | — | 11.5% | |
| LTM Jun 2026 | -$29.91M | +73.9% | — | 1570.9% | |
| FY2025 | -$55.48M | -255.0% | — | 86687.5% | |
| FY2025 | -$60.63M | -52.3% | — | 4490.9% | |
| LTM Mar 2026 | -$69.66M | +46.5% | — | 832.6% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.43M | -31.1% | — | — |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | -$152.57M | -39.7% | — | — |
| LTM Mar 2026 | -$257.08M | -77.0% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$438.96M | -92.9% | — | 5933.5% |
| Peer median (excluding MLTX) | -$58.05M | -33.7% | — | 1570.9% | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.97K | 0 | 0 | 0 | 2.62M |
| Gross Profit | (4.97K) | 0 | 0 | 0 | (2.62M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.52M | 42.05M | 31.8M | 112.77M | 202.86M |
| Selling, General & Admin | 18.05M | 23.01M | 22.32M | 30.32M | 41.97M |
| Operating Expenses | 53.57M | 65.06M | 54.12M | 143.09M | 242.22M |
| Depreciation & Amortization | 4.97K | 164.78K | 370.32K | 1.38M | 2.62M |
| EBITDA | (53.63M) | (64.3M) | (43.61M) | (119.58M) | (219.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (53.58M) | (65.06M) | (54.12M) | (143.09M) | (244.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 7.25M |
| Other Income / Expenses | (61.85K) | 591.73K | 10.14M | 22.13M | 15.12M |
| Income Before Tax | (53.64M) | (64.47M) | (43.98M) | (120.96M) | (229.71M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 4.76K | 36.37K | 94.39K | 282.2K | 611K |
| Net Income | (53.64M) | (49.97M) | (36.01M) | (118.94M) | (227.32M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.45) | (2.20) | (0.73) | (1.89) | (3.53) |
| EPS (Diluted) | (1.45) | (2.20) | (0.73) | (1.89) | (3.53) |
| Weighted Avg Shares | 36.93M | 29.36M | 49.12M | 62.87M | 64.46M |
| Weighted Avg Shares (Diluted) | 36.93M | 29.36M | 49.12M | 62.87M | 64.46M |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.